J López-Torrecilla1, A Palacios Eito2, A Gómez-Caamaño3, J Salinas Ramos4, P Samper Ots5, A Rodríguez Pérez6. 1. Department of Radiation Oncology‑ASCIRES, Hospital General Universitario de Valencia, Av. Tres Cruces, 2, 46014, Valencia, Spain. jltorrecilla@eresa.com. 2. Department of Radiation Oncology, Hospital Universitario Reina Sofía, 14004, Cordoba, Spain. 3. Department of Radiation Oncology, Complejo Hospitalario Universitario de Santiago (CHUS), 15702, Santiago de Compostela, A Coruña, Spain. 4. Department of Radiation Oncology, Hospital General Universitario Santa Maria del Rosell, 30203, Cartagena, Murcia, Spain. 5. Department of Radiation Oncology, Hospital Universitario Rey Juan Carlos, 28933, Móstoles, Madrid, Spain. 6. Department of Radiation Oncology, Hospital Ruber Internacional, 28034, Madrid, Spain.
Abstract
PURPOSE: RENORT is an application (app) developed to assess the role of radiotherapy in the treatment of cancer using the oncology information systems (OIS). METHODS/PATIENTS: The RENORT app was used to analyze the data for all patients seen and/or treated at six radiation oncology departments in Spain in 2019. This app can be used to extract the demographic data, treatment sequence, disease status, and radiotherapy treatments from the ARIA and Mosaiq OIS. RESULTS: A total of 6564 treatments were performed at these six centers in 2019. Most patients (56.9%) were males (females 43.1%). The mean patient age was 64.9 years. The most common treatment types and sites were as follows: metastases/palliative care (25.9%), followed by breast (19.0%), genitourinary (13.7%), lung (10.1%), head and neck (6.0%), rectal (6.0%), gynecological (4.9%), and other (< 4%) cancers. Distribution by disease stage was as follows: breast cancer: 75.5% early stage (stages 0, I, and II); lung: 63.1% advanced stage (III and IV); and head and neck: 72.1% advanced. Treatment intent was curative in 76.5% of cases and palliative in 23.5%. The most common techniques were intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) (41.4%), followed by three-dimensional conformal radiation therapy (3D-CRT) (39.2%); stereotactic body radiotherapy (SBRT) (8.1%); brachytherapy (5.5%); radiosurgery (2.1%); fractionated stereotactic radiotherapy to the brain (1.4%); and intraoperative radiotherapy (1.4%). Hypofractionation was used in 62.3% of curative treatments (mean number of fractions = 16.5). CONCLUSIONS: RENORT is a free app that is available for the two main oncology information systems used in most radiation oncology departments. This app has demonstrated the capacity to extract data from these systems, which in turns allows for a comprehensive analysis and better understanding of the role of radiotherapy in the treatment of cancer.
PURPOSE: RENORT is an application (app) developed to assess the role of radiotherapy in the treatment of cancer using the oncology information systems (OIS). METHODS/PATIENTS: The RENORT app was used to analyze the data for all patients seen and/or treated at six radiation oncology departments in Spain in 2019. This app can be used to extract the demographic data, treatment sequence, disease status, and radiotherapy treatments from the ARIA and Mosaiq OIS. RESULTS: A total of 6564 treatments were performed at these six centers in 2019. Most patients (56.9%) were males (females 43.1%). The mean patient age was 64.9 years. The most common treatment types and sites were as follows: metastases/palliative care (25.9%), followed by breast (19.0%), genitourinary (13.7%), lung (10.1%), head and neck (6.0%), rectal (6.0%), gynecological (4.9%), and other (< 4%) cancers. Distribution by disease stage was as follows: breast cancer: 75.5% early stage (stages 0, I, and II); lung: 63.1% advanced stage (III and IV); and head and neck: 72.1% advanced. Treatment intent was curative in 76.5% of cases and palliative in 23.5%. The most common techniques were intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) (41.4%), followed by three-dimensional conformal radiation therapy (3D-CRT) (39.2%); stereotactic body radiotherapy (SBRT) (8.1%); brachytherapy (5.5%); radiosurgery (2.1%); fractionated stereotactic radiotherapy to the brain (1.4%); and intraoperative radiotherapy (1.4%). Hypofractionation was used in 62.3% of curative treatments (mean number of fractions = 16.5). CONCLUSIONS: RENORT is a free app that is available for the two main oncology information systems used in most radiation oncology departments. This app has demonstrated the capacity to extract data from these systems, which in turns allows for a comprehensive analysis and better understanding of the role of radiotherapy in the treatment of cancer.
Authors: Josep M Borras; Michael Barton; Cai Grau; Julieta Corral; Rob Verhoeven; Valery Lemmens; Liesbet van Eycken; Kris Henau; Maja Primic-Zakelj; Primoz Strojan; Maciej Trojanowski; Agnieszka Dyzmann-Sroka; Anna Kubiak; Chiara Gasparotto; Noemie Defourny; Julian Malicki; Peter Dunscombe; Mary Coffey; Yolande Lievens Journal: Radiother Oncol Date: 2015-05-19 Impact factor: 6.280
Authors: Stephen L Lewis; Sandro Porceddu; Naoki Nakamura; David A Palma; Simon S Lo; Peter Hoskin; Drew Moghanaki; Steven J Chmura; Joseph K Salama Journal: Am J Clin Oncol Date: 2017-08 Impact factor: 2.339
Authors: Pedro C Lara; Aurora Rodríguez; Carlos Ferrer; Jose Javier Aristu; Pedro Jose Prada; Julia Muñoz; Meritxell Arenas; Hector Perez-Montero Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-01 Impact factor: 7.038
Authors: Josep M Borras; Yolande Lievens; Peter Dunscombe; Mary Coffey; Julian Malicki; Julieta Corral; Chiara Gasparotto; Noemie Defourny; Michael Barton; Rob Verhoeven; Liesbeth van Eycken; Maja Primic-Zakelj; Maciej Trojanowski; Primoz Strojan; Cai Grau Journal: Radiother Oncol Date: 2015-05-14 Impact factor: 6.280
Authors: J Jaén Olasolo; E Alonso Redondo; J Expósito Hernández; M D de las Peñas Cabrera; P Cabrera Roldán Journal: Clin Transl Oncol Date: 2007-12 Impact factor: 3.405
Authors: Beth M Beadle; Kai-Ping Liao; Linda S Elting; Thomas A Buchholz; K Kian Ang; Adam S Garden; B Ashleigh Guadagnolo Journal: Cancer Date: 2014-01-13 Impact factor: 6.860
Authors: Mareike K Thompson; Philip Poortmans; Anthony J Chalmers; Corinne Faivre-Finn; Emma Hall; Robert A Huddart; Yolande Lievens; David Sebag-Montefiore; Charlotte E Coles Journal: Br J Cancer Date: 2018-07-31 Impact factor: 7.640